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Abstract
A 27-year old woman presented with primary amenorrhoea and infertility. On examination, she was found to 
have palpable inguinal gonads, normal female external genitalia, a blind-ending vagina with no cervix, almost 
complete absence of axillary and pubic hair, and good breast development. Further investigations confirmed the 
absence of internal female genitalia, the presence of a 46,XY karyotype and testosterone levels in the high normal 
male reference range. A diagnosis of complete androgen insensitivity syndrome was made, based on this clinical 
picture and laboratory findings. Two of her younger siblings were subsequently also diagnosed with this condition. 
She underwent an orchidectomy and is currently on female hormone replacement therapy. At the time of writing 
up this case study, her two younger sisters were still awaiting surgery. 
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Case study
A 27-year old female African patient from Mpumalanga 
was referred to the Endocrinology Clinic at Steve 
Biko Academic Hospital with primary amenorrhoea 
and infertility. She was referred from the cardiology 
department after admission for a supraventricular 
tachycardia. A diagnosis of Wolff-Parkinson-White 
syndrome was made. She had sought help, four years 
prior to this referral, at the gynaecology clinic, but was 
lost to follow-up before the workup was completed. 
She was one of six siblings, with a 26-year old brother and 
four younger sisters. There was no history of consanguinity 
in the family. Of her younger sisters, the youngest, aged 
11, was prepubertal and premenarchal, and the 16-
year old sibling had normal menses. Both the 19-year 
old and the 21-year old siblings experienced primary 
amenorrhoea. The patient reported a usual female 
gender role and female gender identity, and had 
strong maternal feelings. She had already adopted a 
child, but wanted biological children with her husband.
On examination, it was found that she had a normal 
female phenotype, but was relatively tall at 1.71 m. 
She reported that she was much taller than her mother, 
and was the same height as her father. Her body mass 
index was 26. She was found to have palpable inguinal 
gonads which caused some discomfort, and normal 
female external genitalia, with no cliteromegaly or 
ambiguous genitalia present. Her vagina was short 
and blind-ending, with no palpable cervix. The patient 
reported having experienced severe dyspareunia 
for the first two years after becoming sexually active. 
She had good breast development, but an almost 
complete absence of axillary and pubic hair.
A transvaginal sonar confirmed the absence of a 
uterus and intraabdominal ovaries. The inguinal sonar 
detected a right gonad measuring 2.9 x 2.8 x 1.2 cm, 
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Table I: Laboratory findings in the index case
Laboratory test Value Normal
Follicle-stimulating 
hormone 
3.2 Female: 1.8-22.5 IU/l*
Male: 1.3-19.3 IU/l
Luteinising hormone 18.9 Female: 1.2-103 IU/l*
Male: 1.2-8.6 IU/l








3.31 Female: 0.13-1.3 nmol/l
Male: 2.8-15.5 nmol/l
Oestradiol 341 Female: 99-1 590 pmol/l*
Male: < 73-173 pmol/l
*: Depending on the stage of the menstrual cycle
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and a left one measuring 2.5 x 1.1 x 2.2 cm (Figure 1 
a-c). The patient’s laboratory findings are summarised 
in Table II.
The serum testosterone values were in the adult male 
range, with an elevated luteinising hormone (LH). 
Chromosomal studies detected a 46,XY karyotype. 
This confirmed the diagnosis of a form of 46,XY disorder 
of sex development. Taking into account the clinical 
picture, especially the lack   ambiguous genitalia, the 
lack of secondary sexual hair, her female phenotype 
and the sonar findings, in combination with testosterone 
levels in the high normal male range, the diagnosis was 
most likely to be that of complete androgen insensitivity 
syndrome (CAIS). Ovotesticular disorder of sex 
development (especially in view of her high oestradiol 
level), and 5-alpha-reductase type 2 deficiency were 
also considered, but were much less likely in view of the 
clinical findings and special investigations.
The masses are annotated by arrows
Figure 1 a: Sonar of the left inguinal mass
The masses are annotated by arrows
Figure 1 b: Sonar of the right inguinal mass
The masses are annotated by arrows
Figure 1 c: Sonar of the right inguinal mass
Figure 2 a: Sertoli cell nodule
Figure 2 b: Tubuli seminiferi without any spermatogenesis
Figure 2 c: Leydig cell hyperplasia
Case Study: Three siblings with complete androgen insensitivity syndrome
161 2013 Volume 18 No 3JEMDSA
The patient underwent a bilateral gonadectomy, and 
the left gonad measured 4 x 2 x 2 cm. Some of the 
histological findings are depicted in Figure 2 a-c. On 
histology, it was confirmed to be testicular tissue, and 
contained a small nodule measuring 0.5 cm. The right 
testis also measured 4 x 2 x 2 cm, and contained two 
nodules, as well as a cyst that was one centimetre in 
diameter. Neither testis demonstrated spermatogenesis, 
and the nodules were of Sertoli cell origin. Leydig cell 
hyperplasia was prominent in both testes. No ovarian 
tissue was present. The patient’s testosterone level 
dropped postoperatively to a level below 0.34 nmol/l, 
her oestradiol level fell to 139 pmol/l, the LH went up 
to 47.9 IU/l, and the follicle-stimulating hormone (FSH) 
increased to 99.6 IU/l. She was started on hormone 
replacement therapy in the form of Premarin®. 
The patient was extensively counselled before surgery 
regarding her diagnosis and the implications of this 
condition with regard to fertility. She demonstrated 
very good insight into the condition. Unfortunately, her 
husband left her when he found out about her infertility. 
She did not disclose her karyotype to him.
Her two younger sisters (cases 2 and 3) were 
subsequently also evaluated and demonstrated 
almost identical clinical phenotypes, ultrasonographic 
findings and findings on special investigations. Their 
laboratory findings are summarised in Table II. Their 
karyotypes were also found to be 46,XY. They are both 
still awaiting gonadectomies. The youngest sister will 
soon be evaluated by the paediatric endocrinology 
clinic. Unfortunately, we were not able to obtain 
sequencing of the androgen receptor gene for the 
mutation.
Discussion 
CAIS was previously called complete testicular 
feminisation. The reported incidence in the literature 
varies from between approximately one in 20 000 
genetic males in Denmark, to one in 99 000 in the 
Netherlands.1-3 No data are available on how common 
this condition is in South Africa. Only one large case 
series has been described.4 It forms part of a wide 
spectrum of disorders caused by mutations in the gene 
coding for the androgen receptor, leading to resistance 
to androgens.1 Patients can present as phenotypically 
normal females, or with ambiguous genitalia in the 
case of partial androgen insensitivity syndrome, or in 
milder forms, as normal men with undervirilisation or 
fertility problems. These conditions are classified under 
the 46,XY disorders of sex development.5 The rest of this 
discussion will focus on CAIS.
Aetiology
Sentinel work was performed by Marcelli, Tilley and 
Griffin, and McPhaul, Marcelli and Zoppi, who identified 
the different mutations that caused CAIS.6,7Since the 
androgen receptor gene is on the X chromosome, the 
inheritance of this condition is X-linked recessive. It is 
caused by numerous mutations in the gene coding for 
the androgen receptor, leading to severe impairment 
in androgen receptor function. More than a thousand 
mutations have been identified so far.8 Unfortunately, 
we could not obtain sequencing of the gene mutation 
in this family.
Reported abnormalities include missense mutations, 
premature stop codons, deletions and splicing 
abnormalities. Loss-of-function mutations in the coding 
sequence of the androgen receptor can be found in 
most patients with CAIS. Several other defects have 
been identified in recent years.9,10 In a large kindred 
from Soweto, the genetic cause was found to be the 
missense mutation, D732Y, in exon 5 of the androgen 
receptor ligand-binding domain.4 Whereas mutations 
in the androgen receptor are natural, environmental 
endocrine disruptors have been implicated in some 
cases of PAIS.11 
Clinical features
Occasionally, babies are diagnosed with CAIS, even 
prenatally or at birth, because of a discrepancy between 
the karyotype determined through amniocentesis 
and the anatomical gender.1,5 Babies with CAIS have 
phenotypically normal female external genitalia which 
are not ambiguous. A small percentage of these 
children present with inguinal hernias. In retrospective 
studies, the incidence of CAIS was estimated to be 
approximately 0.8-2.4% in girls with inguinal hernias. This 
Table II: Laboratory findings in cases 2 and 3
Laboratory test Case 2 Case 3 Normal
Follicle-stimulating 
hormone 




16.3 13.1 Female: 1.2-103 IU/l*
Male: 1.2-8.6 IU/l









6.23 6.79 Female: 0.13-1.3 nmol/l
Male: 2.8-15.5 nmol/l
Oestradiol 140 97 Female: 99-1 590 pmol/l*
Male: < 73-173 pmol/l
*: Depending on the stage of the menstrual cycle
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was confirmed in a prospective study which found an 
incidence of 1.1%.12 Some patients are also diagnosed 
at a young age because of the presence of palpable 
gonads in the inguinal area or in the labia majora. 
The majority present later during puberty with primary 
amenorrhoea.1,5 It is probably not unusual for patients 
to present much later in developing countries, as 
occurred in our index case. The hallmark of this condition 
on examination is normal breast development, normal 
external female genitalia, with the absence of or 
scanty pubic and axillary hair. Very few other disorders 
of sex development have this combination of clinical 
findings. Other confirmatory findings are an absent, 
short or blind-ending vagina, an absent cervix and often 
palpable gonads in the inguinal area or in the labia 
majora. Testes can also be intra-abdominal. Special 
investigations confirm the absence of a uterus, a 46,XY 
karyotype, and demonstrate serum testosterone levels 
in the normal adult male range.1 Body habitus and 
breast development is similar to that of normal females. 
These patients have a usual female gender identity 
with normal maternal instincts.1,5 
They tend to be taller and larger than would be expected 
following a calculation of mid-parental height. The 
mean height is 171.5 cm, as was also observed in these 
three sisters.13 Usually, the growth pattern follows that of 
girls, but the final achieved height is between that of 
average males and females.14 It is postulated that the Y 
chromosome may have a direct effect on growth and 
body size which is not mediated through the androgen 
receptor. The bone mineral density is decreased in the 
lumbar spine, even in subjects where gonadectomy, 
followed by oestrogen replacement, is performed 
early. This suggests an important role for androgens 
in bone mineral density that cannot be replaced by 
oestrogen.14 
Laboratory findings
Our three patients had typical laboratory findings of 
CAIS. The serum testosterone level was in the normal 
adult male range, or slightly higher.15,16 Serum sex 
hormone-binding globulin concentrations can be 
increased. The testosterone production rate in the 
testes is increased because of an increase in serum LH. 
This is because of resistance to the negative feedback 
of androgens on LH secretion at hypothalamic-pituitary 
level.15 Serum FSH levels are usually normal. Oestrogen 
production is increased by up to 70% higher than that 
of normal men. This oestrogen originates from excess 
testosterone which is peripherally aromatised to 
oestrogen, as well as from the testicular secretion of 
oestrogen.1,17 
Diagnosis
Diagnosis is confirmed by finding a 46,XY karyotype in 
the presence of the above clinical findings, with no 
female internal genitalia detected on imaging, and a 
serum testosterone level in the adult male range.1,5 The 
coding region of the gene that encodes the androgen 
receptor can be sequenced to find the specific 
mutation.5,7 
Management
Gender assignment is not an issue in CAIS, even if 
diagnosed early. These patients should be raised 
as females. Full disclosure now forms part of the 
management plan.18,19 In the case of a minor, the 
parents should be fully informed and counselled, 
preferably by a psychologist who is familiar with this 
condition as disclosure of the diagnosis can lead to 
strong emotional reactions in the parents.20 
The child may receive information based on age 
and understanding, but full disclosure should occur 
before adulthood.18,21 Extensive counselling and 
psychological support may also be required. The 
damage caused by non-disclosure and finding out the 
diagnosis inadvertently, much later, can cause more 
psychological distress.18-20 Female family members 
should also be offered testing. However, there are 
ethical and legal implications, especially with regard 
to patient confidentiality.22 
Dilator therapy to increase vaginal depth and size 
can be started after puberty before sexual activity is 
contemplated.23 This may be sufficient, but occasionally 
vaginoplasty may be necessary.18,19,24 In a recent study, 
the majority of patients reported significant problems 
with desire, arousal and dyspareunia.25 Long-term sexual 
problems can occur, especially if surgical results are 
suboptimal. Sexual problems can occur if the vagina 
remains small after dilator therapy or vaginoplasty.26,27 
The risk of malignancy is increased in patients with 
cryptorchid testes, which is why these three sisters 
were referred for gonadectomies. Germ cell tumours 
or gonadoblastomas can occur in the testes, 
especially if located intra-abdominally, and can 
become malignant. A recent review of adults with 
CAIS estimated the risk of a gonadal malignancy 
developing of approximately 14% (0-22%).28 Older 
figures have estimated the risk as being greater than 
30% by 50 years of age, but these included patients 
with PAIS who, in general, have a much higher risk than 
patients with CAIS.29 
Because the development of these tumours in the 
testes before puberty is very rare, it appears to be 
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safe to defer gonadectomy until after puberty.18,19,28,30 
This will optimise normal breast development and may 
reaffirm the patient’s gender identity. Surgery may be 
deemed necessary earlier in the case of an inguinal 
hernia requiring surgical repair, if the gonads are 
uncomfortable or painful, or if there is doubt about the 
completeness of the androgen resistance. In the last 
scenario, incomplete resistance may lead to virilisation 
during puberty.24,30 
Lifelong hormone replacement therapy is necessary 
post-gonadectomy in adults, or from the time of 
puberty if surgery was performed earlier, especially to 
optimise the already lower-than-normal bone mineral 
density.14,18,19 Whereas biological offspring has been 
impossible in the past, fertility is potentially becoming 
more feasible. If the testes can be preserved after 
gonadectomy, it may possible for these patients to 
have biological children of their own in the future, with 
intracytoplasmic injection of primitive germ cells or 
spermatocytes (which are often present) into a donor 
ovum, and with the assistance of a surrogate.29,31 
Histology
The testes of these patients are of a similar appearance 
to those of cryptorchid testes in boys. The number of 
Leydig cells can be normal or increased. Usually, 
there is no spermatogenesis.29,32 Sertoli cell nodules, as 
found in our index case, or Sertoli cell adenomas, are 
common, but are not premalignant. The epididymis 
and vas deferens are usually absent, but can be 
histologically identified adjacent to the testes in up 
to 36% of patients.32 Carcinoma in situ or germ cell 
malignancies are rarely identified, but usually only 
occur in postpubertal patients.32 
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